title: Combination therapy with interferon alpha and beta to chronic hepatitis C.
abstract: To increase the sustained response (SR) rate in chronic hepatitis C (CHC), we tried a combination therapy with interferon (IFN) alpha and beta. Fifty patients were grouped into 4 groups: group 1H (n=9), HCV serotype 1 and high HCV-RNA titer (over 6 log copies/ml); group 1L (n=11), HCV serotype 1 and low HCV-RNA titer (less than 6 log copies/ml); group 2H (n=23), HCV serotype 2 and high HCV-RNA titer; group 2L (n=7), HCV serotype 2 and low HCV-RNA titer. They were given a total dose of 768 MIU which included natural IFN beta (6 MIU) once daily for 28 consecutive days and then natural IFNalpha (10 MIU) three times a week for 20 weeks. Forty-nine patients with CHC receiving IFN alpha at total dose of 480 MIU served as single therapy group. In combination group, SR rate was achieved in 62%, 44% in 1H, 45% in 1L, 70% in 2H, and 86% in 2L, respectively. In single group, SR rate was achieved in 45, 14, 58, 60, and 82%, respectively. There was no significant difference for SR rate between combination group and single group. However, in patients with HCV-RNA titer between 6-7 log copies/ml of 1H group, SR rate in combination group (67%, 4/6) was significantly higher than that of single group (18%, 3/17) (p<0.05). These data suggest the usefulness of combination therapy with IFN alpha and beta in CHC with serotype 1 having moderately high HCV-RNA titer.
authors.affiliation: The Third Department of Internal Medicine, Ehime University School of Medicine, Shitsukawa, Shigenobu-cho, Onsen-gun, Japan. horiike@m.ehime-u.ac.jp
authors.forename: Norio
authors.initials: N
authors.lastname: Horiike
authors.forename: Hisako
authors.initials: H
authors.lastname: Hino
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Miyaoka
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Miki
authors.forename: Syougo
authors.initials: S
authors.lastname: Yamashita
authors.forename: Bunzo
authors.initials: B
authors.lastname: Matsuura
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kubo
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Ikeda
authors.forename: S M Fazle
authors.initials: SM
authors.lastname: Akbar
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Masumoto
authors.forename: Kojiro
authors.initials: K
authors.lastname: Michitaka
authors.forename: Morikazu
authors.initials: M
authors.lastname: Onji
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000097:blood / Q000302:isolation & purification / Q000378:metabolism*; D012703:Serotyping; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D016899:Interferon-beta